Last reviewed · How we verify
KGX101 and Envafolimab
At a glance
| Generic name | KGX101 and Envafolimab |
|---|---|
| Sponsor | Kangabio AUSTRALIA LTD PTY |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase I Study to Investigate the Safety and Tolerability of KGX101 Monotherapy and Combination Therapy With Envafolimab in Advanced or Metastatic Solid Tumor Patients (PHASE1)
- This is an Open Label, Two-part, Multicenter, Phase I Trial to Investigate the Safety, Tolerability, and PK of KGX101 Monotherapy and Combination Therapy with Envafolimab in Patients with Advanced or Metastatic Solid Tumors. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- KGX101 and Envafolimab CI brief — competitive landscape report
- KGX101 and Envafolimab updates RSS · CI watch RSS
- Kangabio AUSTRALIA LTD PTY portfolio CI